Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Pharmaceutical Business Review
Return to: PBR Home | News

Eisai Launches Anti-Epileptic Zebinix In UK

PBR Staff Writer Published 08 November 2009

Zebinix offers patients improved seizure control with a favorable safety profile

Eisai has reported that the novel once daily anti-epileptic Zebinix (eslicarbazepine acetate) has been launched in the UK as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation.

Zebinix (eslicarbazepine acetate) offers patients improved seizure control with a favorable safety profile. Patients also report improvements in health-related quality of life measures such as 'seizure worry' and 'cognitive function' as well as improvement in the MADRS (Montgomery-Asberg Depression Rating Scale) depressive symptoms scale.

The efficacy, safety and tolerability of Zebinix has been demonstrated in three phase III double-blind, randomised placebo-controlled trials in 1,049 adult patients with partial onset seizures. For each randomised control trial patients were given the option of entering a one year open label extension study.

In these studies eslicarbazepine acetate demonstrated significant and sustained reductions in seizure frequency and significant increases in responder rates.

Nick Burgin, managing director of Eisai, UK, said: "The effective treatment of patients with partial-onset seizures remains a major challenge for clinicians as well as for patients with epilepsy and their families. We are delighted to be bringing patients such a promising new treatment.

"The launch of eslicarbazepine acetate will further help us to fulfil our corporate mission of 'human health care' (hhc) by providing innovative, high quality medicines to meet the ever changing unmet medical needs of patients and their families as well as health care professionals."

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.